HLBBF.US H. Lundbeck A/S

Healthcare Pharmaceuticals USA Stocks
11.37 USD
Close of Nov 15, 2026
5.52 9.09
Market cap
USD 9.02B
P/E
14.2x
P/B
1.68x
ROE
18.8%
Dividend yield
2.51%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HLBBF.US undervalued?

Graham number
Price11.37
Graham value11.04
Premium3.0%

HLBBF.US trades 3.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

H. Lundbeck A/S fundamental analysis

No fundamental analysis for H. Lundbeck A/S yet.

H. Lundbeck A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About H. Lundbeck A/S

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Ci…

Full company profile